U.S. markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
818.03-4.93 (-0.60%)
At close: 04:00PM EDT
818.04 +0.01 (+0.00%)
After hours: 05:11PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close822.96
Bid816.56 x 800
Ask822.00 x 800
Day's Range808.90 - 833.28
52 Week Range668.00 - 847.50
Avg. Volume523,431
Market Cap88.805B
Beta (5Y Monthly)0.19
PE Ratio (TTM)21.64
EPS (TTM)37.80
Earnings DateNov 02, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est907.48
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
-1% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for REGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Regeneron Pharmaceuticals, Inc.
    Analyst Report: Regeneron Phars, IncRegeneron is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis. Founded in 1988, Regeneron has collaborated with Amgen, Procter & Gamble, Bayer, Sanofi, and Japan's Sumitomo Chemical. The company is a component of the S&P 500, has more than 11,850 employees worldwide, and is based in Tarrytown, New York.
    Fair Value
    Economic Moat
    17 days agoArgus Research
View more
  • Simply Wall St.

    Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Motley Fool

    Stock Split Watch: Is Regeneron Pharmaceuticals Next?

    Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market value of a company, nor does it alter the value of any investor's holdings, but it does bring down the price of each individual share. Of course, it's impossible to predict which company may perform a stock split with 100% accuracy, but a top performer that has been setting new share price highs could make a good candidate.

  • GlobeNewswire

    Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

    If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also reviewing odronextamab Marketing Authorization Application TARRYTOWN, N.Y., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for odronextam